Table 3

ROC curve analysis of serum NRP-1 and ANG-2 performance characteristics among the studied groups

AUC95% CIP valueCut-offSensitivitySpecificity
Serum NRP-1
Patients with HCC (group I) vs patients with liver cirrhosis (group II)0.8010.709 to 0.875<0.001*>141872.087.8
Patients with HCC (group I) vs healthy controls (group III)0.9920.949 to 1.000<0.001*>36796.098.0
Serum ANG-2
Patients with HCC (group I) vs patients with liver cirrhosis (group II)0.7480.651 to 0.830<0.001*>278060.073.5
Patients with HCC (group I) vs healthy controls (group III)0.8090.719 to 0.881<0.001*>267966.084.0
Serum AFP
Patients with HCC (group I) vs patients with liver cirrhosis (group II)0.7620.666 to 0.842<0.001*>188.074.075.5
Patients with HCC (group I) vs healthy controls (group III)0.9830.934 to 0.998<0.001*>7.996.090.0
Combined analysis (serum NRP-1+AFP)
Patients with HCC (group I) vs patients with liver cirrhosis (group II)0.8250.736 to 0.894<0.001*–64.0100.0
Patients with HCC (group I) vs healthy controls (group III)0.9940.952 to 1.000<0.001*–96.0100.0
  • *P<0.05 significant.

  • AFP, alpha-fetoprotein; ANG-2, angiopoietin-2; AUC, area under the curve; HCC, hepatocellular carcinoma; NRP-1, neuropilin-1; ROC, receiver operating characteristic.